Monitoring response to gefitinib in nude mouse tumor xenografts by 18 F-FDG microPET-CT: correlation between 18 F-FDG uptake and pathological response

World Journal of Surgical Oncology

Lian-Feng Zhang³  Xiao-Ying Li³  Kai Gao³  Ying Liang¹  Ning Wu¹  Li-Na Zhou² 

[1] PET-CT Center, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing 100021, China;Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing 100021, China;Key Laboratory of Human Disease Comparative Medicine, Ministry of Heath, Institute of Laboratory Animal Science, Peking Union Medical College, Chinese Academy of Medical Science, No.5, Pan Jia Yuan Nan-li, Beijing 100021, China

关键词: Targeted therapy;    Tomography;    Positron emission tomography;    Fluorodeoxyglucose;    Xenograft;   

Others  :  1146264
DOI  :  10.1186/s12957-015-0505-x

 received in 2014-07-28, accepted in 2015-02-09,  发布年份 2015

【 摘 要 】

Background

The purpose of this study is to investigate whether ¹⁸ F-fluorodeoxyglucose (FDG) micro-positron emission tomography-computed tomography (microPET-CT) can be used to monitor a metabolic response to gefitinib in nude mouse tumor xenografts.

Methods

Sixteen nude mice were implanted with human A431 epidermoid carcinoma cells and ten with human A549 lung adenocarcinoma cells, and the tumors were allowed to grow to an approximate size of 150 mm³. Ten and five of these mice, respectively, received intragastric gefitinib (100 mg/kg) once daily for 14 days, whereas six and five, respectively, received sterile water. Tumor metabolic activity was assessed by ¹⁸ F-FDG microPET imaging before treatment (day 0) and on days 2, 7, and 14. Tumor uptake of ¹⁸ F-FDG was determined from a region-of-interest drawn around the tumor, and the maximum percentage injected dose per gram (%ID/g_max) was calculated. Tumor volume measured on day 14 by microCT was used to categorize tumors as sensitive, stable, or resistant to gefitinib, and pathologic changes in these tumors were analyzed.

Results

On day 2, the average changes in ¹⁸ F-FDG uptake by A431 tumors sensitive, stable, and resistant to gefitinib were −30.92% ± 6.66%, −5.68% ± 6.95%, and 7.72% ± 3.85%, respectively (P < 0.05 each), with no significant differences in the sizes of tumors sensitive and stable to gefitinib (P = 0.169). On day 7, sensitive tumors were significantly smaller than stable tumors (P = 0.034). On day 14, areas of necrosis were observed in gefitinib-sensitive tumors, with tumor necrosis ratios differing significantly among the sensitive, stable, and control groups (P < 0.05 each). In mice implanted with A549 cells, however, tumor ¹⁸ F-FDG uptake, volume, and percent necrosis did not differ significantly between gefitinib-treated and untreated mice on days 0, 2, 7, and 14 (P > 0.05 each).

Conclusions

F-FDG uptake is a sensitive method of detecting metabolic changes in tumors associated with therapy in vivo.

【 授权许可】

   
2015 Zhou et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al.. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003; 21:2237-46.
• [2]Cohen EEW, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM et al.. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005; 11:8105-8.
• [3]Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004; 22:77-85.
• [4]Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002; 38 Suppl 5:S60-5.
• [5]Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M et al.. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005; 11:1167-73.
• [6]He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA et al.. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012; 18:1790-7.
• [7]van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT et al.. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008; 453:417-31.
• [8]Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW et al.. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005; 11:2879-82.
• [9]Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al.. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18 F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006; 24:5366-72.
• [10]Vliegen RFA, Beets-Tan RG, Vanhauten B, Driessen A, Oellers M, Kessels AG et al.. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol. 2008; 184:457-64.
• [11]Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18 F-FDG PET. J Nucl Med. 2005; 46:1144-50.
• [12]Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME et al.. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12:5659-67.
• [13]Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I et al.. Early [18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012; 18:220-8.
• [14]Aukema TS, Kappers I, Olmos RAV, Codrington HE, van Tinteren H, van Pel R et al.. NEL Study Group: is 18 F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010; 51:1344-8.
• [15]Aliaga A, Rousseau JA, Cadorette J, Croteau É, van Lier JE, Lecomte R et al.. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol. 2007; 9:144-50.
• [16]Gan SY, Zhong XY, Xie SM, Li SM, Peng H, Luo F. Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. Chin J Cancer. 2010; 29:300-5.
• [17]Almuhaideb A, Papathanasiou N, Bomanji J. 18 F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011; 31:3-13.
• [18]Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S et al.. Correlation of 18 F-FLT and 18 F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34:1610-6.
• [19]de Geus-Oei LF, van Laarhoven HWM, Visser EP, Hermsen R, van Hoorn BA, Kamm YJL et al.. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008; 19:348-52.
• [20]Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R et al.. Value of 18 F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006; 12:97-106.
• [21]Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J et al.. Difference in prognostic significance of maximum standardized uptake value on [18 F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol. 2011; 41:890-6.
• [22]Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y et al.. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol. 2011; 101:291-7.
• [23]Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [18 F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012; 39:840-5.
• [24]Wieder HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ et al.. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005; 46:2029-34.
• [25]Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S-50.
• [26]Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T et al.. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008; 59:203-10.
• [27]Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003; 30:274-80.